Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 516

1.

Coronary artery bypass grafting after aprotinin: are we doing better?

Beckerman Z, Shopen Y, Alon H, Cohen O, Nir RR, Adler Z, Bolotin G.

J Thorac Cardiovasc Surg. 2013 Jan;145(1):243-8. doi: 10.1016/j.jtcvs.2012.09.032. Epub 2012 Oct 13.

2.

Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.

Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R.

Anesth Analg. 2008 Nov;107(5):1469-78. doi: 10.1213/ane.0b013e318182252b.

PMID:
18931201
3.

Aprotinin is not associated with postoperative renal impairment after primary coronary surgery.

Lindvall G, Sartipy U, Ivert T, van der Linden J.

Ann Thorac Surg. 2008 Jul;86(1):13-9. doi: 10.1016/j.athoracsur.2008.03.033.

PMID:
18573391
4.

Removal of aprotinin from low-dose aprotinin/tranexamic acid antifibrinolytic therapy increases transfusion requirements in cardiothoracic surgery.

Vonk AB, Meesters MI, Schats J, Romijn JW, Jansen EK, Boer C.

Interact Cardiovasc Thorac Surg. 2011 Feb;12(2):135-9. doi: 10.1510/icvts.2010.250936. Epub 2010 Nov 12.

PMID:
21075830
5.

The safety of aprotinin and lysine-derived antifibrinolytic drugs in cardiac surgery: a meta-analysis.

Henry D, Carless P, Fergusson D, Laupacis A.

CMAJ. 2009 Jan 20;180(2):183-93. doi: 10.1503/cmaj.081109. Epub 2008 Dec 2. Review.

6.

A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial).

Bokesch PM, Szabo G, Wojdyga R, Grocott HP, Smith PK, Mazer CD, Vetticaden S, Wheeler A, Levy JH.

J Thorac Cardiovasc Surg. 2012 May;143(5):1022-9. doi: 10.1016/j.jtcvs.2011.06.001. Epub 2011 Jul 2.

7.

Intraoperative antifibrinolysis and blood-saving techniques in cardiac surgery. Prospective trial of 3 antifibrinolytic drugs.

Penta de Peppo A, Pierri MD, Scafuri A, De Paulis R, Colantuono G, Caprara E, Tomai F, Chiariello L.

Tex Heart Inst J. 1995;22(3):231-6.

8.

Fibrinolytic inhibitors in off-pump coronary surgery: a prospective, randomized, double-blind TAP study (tranexamic acid, aprotinin, placebo).

Vanek T, Jares M, Fajt R, Straka Z, Jirasek K, Kolesar M, Brucek P, Maly M.

Eur J Cardiothorac Surg. 2005 Oct;28(4):563-8.

PMID:
16125959
9.

The impact of aprotinin on blood loss and blood transfusion in off-pump coronary artery bypass grafting.

Bittner HB, Lemke J, Lange M, Rastan A, Mohr FW.

Ann Thorac Surg. 2008 May;85(5):1662-8. doi: 10.1016/j.athoracsur.2008.01.087.

PMID:
18442562
10.

Low dose tranexamic acid effect on post-coronary artery bypass grafting bleeding.

Esfandiari BR, Bistgani MM, Kabiri M.

Asian Cardiovasc Thorac Ann. 2013 Dec;21(6):669-74. doi: 10.1177/0218492312466391. Epub 2013 Jul 9.

PMID:
24569324
11.

Perioperative renal outcome in cardiac surgical patients with preoperative renal dysfunction: aprotinin versus epsilon aminocaproic acid.

Maslow AD, Chaudrey A, Bert A, Schwartz C, Singh A.

J Cardiothorac Vasc Anesth. 2008 Feb;22(1):6-15. doi: 10.1053/j.jvca.2007.07.017. Epub 2007 Nov 7.

PMID:
18249324
12.

Effects of tranexamic acid on postoperative bleeding and related hematochemical variables in coronary surgery: Comparison between on-pump and off-pump techniques.

Casati V, Della Valle P, Benussi S, Franco A, Gerli C, Baili P, Alfieri O, D'Angelo A.

J Thorac Cardiovasc Surg. 2004 Jul;128(1):83-91.

13.

The effect of antifibrinolytic prophylaxis on postoperative outcomes in patients undergoing cardiac operations.

Koul A, Ferraris V, Davenport DL, Ramaiah C.

Int Surg. 2012 Jan-Mar;97(1):34-42. doi: 10.9738/CC75.1.

14.

Tranexamic acid and aprotinin in low- and intermediate-risk cardiac surgery: a non-sponsored, double-blind, randomised, placebo-controlled trial.

Later AF, Maas JJ, Engbers FH, Versteegh MI, Bruggemans EF, Dion RA, Klautz RJ.

Eur J Cardiothorac Surg. 2009 Aug;36(2):322-9. doi: 10.1016/j.ejcts.2008.11.038. Epub 2009 Feb 27.

PMID:
19250838
15.
16.

Tranexamic acid compared with high-dose aprotinin in primary elective heart operations: effects on perioperative bleeding and allogeneic transfusions.

Casati V, Guzzon D, Oppizzi M, Bellotti F, Franco A, Gerli C, Cossolini M, Torri G, Calori G, Benussi S, Alfieri O.

J Thorac Cardiovasc Surg. 2000 Sep;120(3):520-7.

17.

Mortality associated with administration of high-dose tranexamic acid and aprotinin in primary open-heart procedures: a retrospective analysis.

Sander M, Spies CD, Martiny V, Rosenthal C, Wernecke KD, von Heymann C.

Crit Care. 2010;14(4):R148. doi: 10.1186/cc9216. Epub 2010 Aug 3.

18.

Current antifibrinolytic therapy for coronary artery revascularization.

Trudell J, McMurdy N.

AANA J. 2008 Apr;76(2):121-4. Review.

PMID:
18478817
19.

[Effects of topical applications of aprotinin and tranexamic acid on blood loss after open heart surgery].

Yasim A, A┼čik R, Atahan E.

Anadolu Kardiyol Derg. 2005 Mar;5(1):36-40. Turkish.

Supplemental Content

Support Center